Crestor, Serevent Safety Issues Push Vioxx Out Of Spotlight In Senate Hearing
Executive Summary
FDA's focus following the Senate Finance Committee hearing on the Vioxx withdrawal is on defending the safety of five other drugs challenged by one of its safety reviewers
You may also be interested in...
Arava, Avandia's Divergent Paths: FDA Strengthens Arava Label Warning
As FDA advisory committee debated the fate of Avandia, the agency bolsters liver warning on Arava, another drug David Graham suggested be removed from the market.
Serevent, Foradil Use With Steroids Should Be Strongly Urged In Labeling
Labeling for GSK's Serevent and Novartis/Schering's Foradil should include a stronger recommendation that the long-acting beta agonist bronchodilators be used concomitantly with inhaled corticosteroids, FDA's Pulmonary-Allergy Drugs Advisory Committee said
Serevent, Foradil Use With Steroids Should Be Strongly Urged In Labeling
Labeling for GSK's Serevent and Novartis/Schering's Foradil should include a stronger recommendation that the long-acting beta agonist bronchodilators be used concomitantly with inhaled corticosteroids, FDA's Pulmonary-Allergy Drugs Advisory Committee said